key: cord-0768532-6vm8t6bn
authors: Bliddal, S.; Banasik, K.; Pedersen, O. B.; Nissen, I.; Cantwell, L.; Schwinn, M.; Tulstrup, M.; Westergaard, D.; Ullum, H.; Brunak, S.; Tommerup, N.; Feenstra, B.; Geller, F.; Ostrowski, S. R.; Groenbaek, K.; Nielsen, C. H.; Nielsen, S. D.; Feldt-Rasmussen, U.
title: Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients
date: 2021-01-25
journal: nan
DOI: 10.1101/2021.01.22.21249945
sha: 8b37cc1e2c5980b1ecb5a7cb78facd55d2337b22
doc_id: 768532
cord_uid: 6vm8t6bn

Background: Reports of persistent symptoms after hospitalization with COVID-19 have raised concern of a long COVID syndrome. This study aimed at characterizing acute and persistent symptoms in non-hospitalized patients with polymerase chain reaction (PCR) confirmed COVID-19. Methods: Cohort study of 445 non-hospitalized participants identified via the Danish Civil Registration System with a SARS-CoV-2-positive PCR-test and available biobank samples for genetic analyses. Participants received a digital questionnaire on demographics and COVID-19-related symptoms. Persistent symptoms: symptoms >four weeks (in sensitivity analyses >12 weeks). Results: 445 participants were included, of whom 34% were asymptomatic. Most common acute symptoms were fatigue, headache, and sneezing, while fatigue and reduced smell and taste were reported as most severe. Persistent symptoms, most commonly fatigue and memory and concentration difficulties, were reported by 36% of 198 symptomatic participants with follow-up >four weeks. Risk factors for persistent symptoms included female sex (women 44% vs. men 24%, odds ratio 2.7, 95%CI:1.4-5.1, p=0.003) and BMI (odds ratio 1.1, 95%CI:1.0-1.2, p=0.001). Conclusion: Among non-hospitalized PCR-confirmed COVID-19 patients one third were asymptomatic while one third of symptomatic participants had persistent symptoms illustrating the heterogeneity of disease presentation. These findings should be considered in future health care planning and policy making related to COVID-19.

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-52

CoV-2), has by December 2020 affected more than 82 million people worldwide and has been associated with 53 2 million deaths leading to a global health and financial crisis [1] . Established risk factors related to dying with 54 the disease include high age, male sex and preexisting comorbidities [2, 3, 4] . A meta-analysis of 24,410 55 COVID-19 patients found that the most common symptoms were fever, cough, fatigue, and hyposmia [5] . 56

However, not all exposed individuals catch the disease and not all who have the disease develop symptoms 57 [6, 7] . Thus, there is a knowledge gap of individual resilience and risk factors determining the disease trajectory. 58

In the wake of the initial phase of the COVID-19 pandemic, several observational studies, patient groups and 59 case series have reported persistent symptoms including reduced respiratory capacity [8] , fatigue and 60 hyposmia [9,10,11]. In a follow-up study of 143 Italians discharged after hospitalization due to 61 87.4% still experienced COVID-19-related symptoms at two months after symptom start, and more than half 62 of the patients reported persistent fatigue [12] . Similarly, Jacobs et al found that fatigue was the most prevalent 63 symptom 35 days post-hospitalization in 183 participants from the United States, and the majority of 64 participants reported reduced quality of life and both physical and mental health problems [13] . A recent 65

Chinese study presented 6-month follow-up data from 1,733 hospitalized patients, of whom 63% still 66 experienced fatigue and muscle weakness [14] . Clinical and public health interests are therefore no longer 67 limited to information on mortality and clinical outcomes in hospitalized patients, but also to recovery and 68 long-term consequences of COVID-19 post-hospitalization. Among other initiatives, this has led to the Post-69

Hospitalization COVID-19 study (PHOSP-COVID) in the United Kingdom aiming at long-term follow-up of 70

Most studies on COVID-19 symptoms have recruited participants among hospitalized patients or patients 77 attending outpatient clinics or specialized units, or support groups dealing with the consequences of COVID-78 19 [5, 9, 20, 21] . This confers a selection bias likely overestimating the true prevalence of symptoms and 79 symptom severity. Thus, there is an academic knowledge gap in symptomatology among unselected non-80 hospitalized patients. 81

The aim of the present study was to determine the nature and prevalence of acute and persistent symptoms in Invitations were sent to participants via e-Boks between June 24 th and August 15 th 2020 together with written 96 project information and a link to a questionnaire on demographic data and symptomatology related to COVID-97 19. Interested participants could contact a call center between July 27 th and August 28 th 2020 to receive oral 98 information on the project and provide oral consent prior to receiving a digital link for written consent. The 99 last questionnaire was received digitally by October 31 st 2020. 100 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in System with a PCR-confirmed positive test for SARS-CoV-2  102   and an available biobank sample for genetic analyses with no history of hospitalization due to COVID-19 were  103 eligible for this study (n=4,421). Hospitalization due to COVID-19 was defined as a hospital admission lasting 104 longer than 12 hours within 14 days of a positive PCR-test for SARS-CoV-2. Date of COVID-19 diagnosis 105 and hospitalization status were accessed through the national register for COVID-19 surveillances (EpiMiBa). 106

Non-hospitalized participants with a valid written consent and a completed questionnaire were included in this 107 study. 108

All participants received a link in their e-Boks to a questionnaire with a large number questions on 110 demographic data as well as history and symptoms related to COVID-19. The questionnaire was to a large 111 extent based on a previously validated questionnaire used as part of the Danish Blood Donor Study [27] . 112

Questions on lifestyle factors, demographics and co-morbidities included smoking status, height and weight, 113 occupation, educational level, and the possibility to select the following chronic diseases (using layman terms): 114 Asthma, allergy (other than asthma), diabetes mellitus, hyperthyroidism, hypothyroidism, high blood pressure, 115 heart attack, chest pain (angina pectoris), stroke, chronic bronchitis or big lungs or smokers lungs (emphysema, 116 COPD), osteoarthritis, rheumatoid arthritis, osteoporosis, cancer, other. 117

Queries on symptomatology related to COVID-19 included the questions "Have you had a feeling of being ill 118 in the period since February 1 st 2020?" and if "yes" the following symptoms were listed with answer options 119 of "No", "Yes, a little", "Yes, some", "Yes, a lot", "Don't know": Fever, chills, runny or stuffy nose, reduced 120 sense of smell, reduced sense of taste, sneezing, sore throat, coughing, shortness of breath, headache, muscle 121 and joint pain, chest pain, tiredness and exhaustion [fatigue], difficulties concentrating or remembering, lack 122 of appetite, coloured sputum, red runny eyes, nausea, vomiting, diarrhoea, stomach pain, other. To clarify 123 persistence of symptoms, the questionnaire included the question "Do you still have symptoms" and if the 124 participant answered "yes", the same list of symptoms was provided albeit without the option of ranking the 125 degree of symptoms. 126 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Symptoms commencing between 28 days before the positive SARS-CoV-2 PCR-test result and 14 days after 127 the test result were included as COVID-19-related symptoms ( Supplementary Fig. S1 online). Persistent 128 symptoms were defined as symptoms lasting more than four weeks; these could be ongoing symptoms at the 129 time of filling in the questionnaire in case of a follow-up time of more than four weeks from symptom onset. 130

Alternatively, a stop date could be given in case of a reported symptom lasting more than four weeks from 131 symptom onset to symptom stop. In sensitivity analyses, persistent symptoms lasting more than 12 weeks were 132 explored based on the same selection criteria (12 weeks instead of four weeks). These time limits were in 133 accordance with the time frame for ongoing symptomatic COVID-19 and post-COVID-19-syndrome, 134 respectively, suggested by the National Institute for Health and Care Excellence in the United Kingdom [19] . 135

Demographic data were presented as appropriate by means and standard deviations (SD) or medians and inter-137 quartile range (IQR). Logistic regression analyses included as covariates: sex (male-female), age, BMI, 138 smoking status (non-smoker vs. ever smoker), comorbidity (yes-no based on composite scores of self-reported 139 chronic disease), work in the health care sector (yes-no), and time to questionnaire (weeks). The latter was 140 included to account for any potential recall bias as the time periods between the PCR test and the questionnaire 141 (in analyses of asymptomatic vs. symptomatic participants) or between the symptom start and the questionnaire 142 (in analyses of persistent vs. no persistent symptoms among symptomatic individuals). Among the health care 143 workers, almost all reported having patient contact [not specified if COVID-related] and thus patient contact 144 was not included in the model. In the logistic regression analyses of risk of acute and persistent symptoms, we 145 used a composite score (any symptom vs no symptom) across all acute and persistent symptoms, respectively. 146

The composite score for acute symptoms included any symptom, regardless of reported severity. P-values 147 reported are based on Welch Two Sample t-test for normally distributed traits and Fisher's Exact for 148 categorical traits. All statistical analyses and preparation of figures were performed by R version 3.5.0 (the R 149 foundation, www.r-project.org). 150 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

The study was part of the "Epidemiology and Genetics of COVID-19" study approved by the National 152

Committee on Health Research Ethics (ID: NVK 2003947) and by the Data Protection Agency (ID: P-2020-153 356). All participants provided oral and written consent to participate. 154 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

A total of 445 Danish non-hospitalized COVID-19 participants were included (see Fig. 1 for flow chart of the 156 inclusion process). 157 158 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 25, 2021. ; https://doi.org/10.1101/2021.01.22.21249945 doi: medRxiv preprint Most participants had been tested during the Spring of 2020 (Table 1 ). More women than men participated in 159 the study and significantly more women worked in the health care sector and had patient contact (not specified 160 if COVID-related). Also, the median date for PCR-testing of the included women was one month earlier than 161 that of men (Table 1 ). There were no other significant differences in demographic data between men and 162 women ( Table 1) . Less than half of the participants reported preexisting comorbidities; most commonly allergy 163 (28%), hypertension (15%), osteoarthritis (17%), and asthma (8%) (see Supplementary Fig. S2 Completely asymptomatic COVID-19 was reported by 34% of participants. There were no significant 168 differences in sex, smoking status, comorbidities, health care worker status or BMI between those reporting 169 symptoms and those without symptoms. Asymptomatic participants had more often been tested towards the 170 end of the study inclusion period (weeks from PCR to questionnaire; adjusted odds ratio (OR) 1.06 171 95%CI:1.02-1.09, p=0.0008) (depicted in Supplementary Fig. S3 online), and were slightly older (OR for 172 symptoms 0.98 (0.97-0.99), p=0.004). 173

Among the 238 participants experiencing symptoms, 55% of women and 52% of men had a sudden onset of 174 symptoms arising within a few hours. Characteristics of symptomatic participants are presented in Table 2 . 175

Significantly more symptomatic women than men were working in the health care system, had contact with 176 patients in their work and had been tested slightly earlier in the year ( Table 2 ). The most common symptoms 177 in the acute phase of COVID-19 were fatigue (95%), headache (82%), and sneezing (76%) ( Fig. 2A) . However, 178 the symptoms most often reported as being severe were reduced smell, fatigue, and reduced taste ( Fig. 2A) . 179

Excluding all participants with comorbidities did not change the symptom presentation (Fig. 2B) . perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in participants with a SARS-CoV-2-positive PCR test. Only participants with symptom start between 28 days 189 before and 14 days after the PCR-test were included. Figure A , all symptomatic participants (n=238). Figure  190 B, symptomatic participants without comorbidities (n=105). 191

Abbreviations: PCR, polymerase chain reaction. SARS-CoV-2, severe acute respiratory syndrome coronavirus 192 2. 193 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 25, 2021. ; https://doi.org/10.1101/2021.01.22.21249945 doi: medRxiv preprint Persistent symptoms 194 Most symptomatic participants experienced symptom cessation within two weeks (n=137, women in median 195 14 days (range:1-112), men in median 12 days (1-138)). Ongoing symptoms at the time of filling in the 196 questionnaire were reported by more than 35% of participants (median time from symptom start 90 days (range 197 5-197)). Follow-up for more than four weeks was available from 198 symptomatic participants among whom 198 persistent symptoms were reported by 36% (44% of women and 24% of men). The most common persistent 199 symptoms were fatigue (16%), concentration or memory difficulties (13%), reduced sense of smell (10%), and 200

shortness of breath (10%) (Fig. 3) . Among participants with more than 12 weeks of follow-up since symptom 201 start (n=129), 40% (48% of women and 23% of men) still had symptoms, especially fatigue (16%) and 202 concentration difficulties (13%), following the same pattern as those with a shorter follow-up period (Fig. 3) . 203 perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 25, 2021. ; https://doi.org/10.1101/2021.01.22.21249945 doi: medRxiv preprint Persistent symptoms after COVID-19. In dark blue, persistent symptoms for more than four weeks in the 198 206 non-hospitalized participants with symptoms and a follow-up time of more than four weeks and in light blue, 207 persistent symptoms for more than 12 weeks in the 129 non-hospitalized participants with symptoms and a 208 follow-up time of more than 12 weeks. 209 210

The risk of persistent symptoms more than four weeks after symptom start was significantly increased in 212 women compared to men (OR 2.7 95%CI:1.4-5.2, p=0.003 (Table 3) ). Furthermore, there was an increased 213 risk of persistent symptoms with increasing BMI (OR 1.1 95%CI:1.0-1.2, p=0.001 (Table 3) ). No other 214 covariates were significantly associated with the risk of persistent symptoms. Female sex and BMI were also 215 the only significant risk factors for persistent symptoms in the 129 participants with a follow-up period of more 216 than 12 weeks (see supplementary Table S1 available online). 217

More women than men worked in the health care sector (table 1 and 2). Thus, we re-ran analyses of risk factors 218 for persistent symptoms by only including the 117 women with follow-up of more than four weeks. Doing so, 219 BMI was still a significant risk factor (adjusted OR 1.2 95%CI:1.1-1.3, p=0.003), but being a health care 220 worker was not (OR 1.5 95%CI:0.6-3.8, p=0.39). 221 Furthermore, we depicted acute and persistent symptoms according to sex (Fig. 4 ). Men and women had a 222 similar prevalence of fatigue in the acute phase ( Fig. 4 left hand side). In participants with persistent symptoms, 223 fatigue was the most common persistent symptom in both men and women, but the prevalence of persistent 224 fatigue was almost twice as high in women compared to men (28% vs. 15%, OR 2.2 95%CI:1.0-4.7, p=0.05, 225 right hand side of Fig. 4) . 226 227 228 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The percentage of acute (red panel to the left) and persistent (blue panel to the right) symptoms in non-231 hospitalized COVID-19 participants according to sex. Persistent symptoms were defined as lasting more than 232 four weeks. A, prevalence of reported acute (total n=148) and persistent symptoms (total n=126) in women. 233 B, prevalence of reported acute (total n=90) and persistent symptoms (total n=72) in men. 234 235 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in resemblance to that of many autoimmune diseases [42] . Unfortunately, the present study did not have 284 laboratory data to assess either initial or persistent immunological response against SARS-CoV-2 and did not 285 have data for retesting for SARS-CoV-2 to ascertain resolution of the viral load in participants with persistent 286 symptoms. However, previous studies have found a poor correlation between the risk of persistent symptoms 287 and objective measures of disease despite performing a wide range of clinical and laboratory tests in COVID-288 19 patients either during the acute phase or at follow-up [9,28]. Also, a negative SARS-CoV-2 PCR-test as a 289 sign of recovery has been criticized for not corresponding to the patients' perception of (or lack of) recovery 290 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in In conclusion, even among non-hospitalized PCR-confirmed SARS-CoV-2-positive participants, more than 326 one third reported persistent symptoms after four and 12 weeks, respectively. The most prevalent persistent 327 symptoms were fatigue and memory and concentration difficulties. Contrary to this, 34% of non-hospitalized 328 patients were asymptomatic in the acute phase of the disease stressing the importance of testing near contacts. 329

The high prevalence of both patients with persistent symptoms and of asymptomatic patients bear witness to 330 the heterogeneity of the disease presentation. Although data should be reproduced due to possible limitations 331 of survival or recall bias, these findings should be taken into account in future health care planning and policy 332 making related to COVID-19 prevention, detection, treatment and follow-up. 333

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The percentage of acute (red panel to the left) and persistent (blue panel to the right) symptoms in non-489 hospitalized COVID-19 participants according to sex. Persistent symptoms were defined as lasting more than 490 four weeks. A, prevalence of reported acute (total n=148) and persistent symptoms (total n=126) in women. 491 B, prevalence of reported acute (total n=90) and persistent symptoms (total n=72) in men. 492 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

The Johns Hopkins Coronavirus Resource Center

Characteristics of and Important Lessons From the Coronavirus Disease 337 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese 338 Center for Disease Control and Prevention

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. 340 Lancet

Risk factors of critical & mortal COVID-19 cases: A systematic literature review and 342 meta-analysis

The prevalence of symptoms in 24,410 adults infected by the novel coronavirus 344 (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 345 countries

Asymptomatic patients as a source of COVID-19 infections: A systematic review 347 and meta-analysis

Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing 349 Facility

Long term respiratory complications of covid-19

Persistent fatigue following SARS-CoV-2 infection is common and independent of 352 severity of initial infection

Six month follow-up of self-reported loss of smell during the COVID-19 pandemic

Online ahead of print

Prolonged complaints of chemosensory loss after COVID-19

Persistent Symptoms in Patients After Acute COVID-19

Persistence of symptoms and quality of life at 35 days after hospitalization for 359 COVID-19 infection

6-month consequences of COVID-19 in patients discharged from hospital: a cohort 361 study

COVID consortium & Leicester University. The Post-hospitalisation COVID-19 study

Led Research for COVID-19. Report: What Does COVID-19 Recovery Actually Look Like? 403

Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 405 syndrome?

The Kids Are Not Alright: A Preliminary Report of Post-COVID Syndrome in 407 University Students

Meeting the challenge of long COVID

Measuring symptomatic and functional recovery in patients with community-acquired 411 pneumonia

Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: 413 long-term follow-up

One-year outcomes and health care utilization in survivors of severe acute 415 respiratory syndrome

Sex bias in autoimmunity

Updated NICE guidance on chronic fatigue syndrome

Exercise therapy for chronic fatigue 421 syndrome

Could Cognitive Behavioural Therapy Be an Effective Treatment for Long 423 COVID and Post COVID-19 Fatigue Syndrome? Lessons from the Qure Study for Q-Fever 424 Fatigue Syndrome

Support for Rehabilitation: Self-Management after COVID-19 Related 426 Illness

Management of post-acute covid-19 429 in primary care

Long COVID guidelines need to reflect lived experience

Rapid implementation of mobile technology for real-time epidemiology of COVID-432 19

Risk of COVID-19 in health-care workers in Denmark: an observational cohort study

Spread of SARS-CoV-2 in the Icelandic Population

 442 We highly appreciate our collaboration with the Danish COVID-19 Genetic Consortium (Supplementary 443